Clinical trial

Study of Comparing the Different Effect of DPP-4 Inhibitors and Sulfonylurea by Using "Biphase-Hyperglycemic Clamp"

NCT01660386

Study summary

ClinicalTrials.gov

Study of Comparing the Different Effect of DPP-4 Inhibitors and Sulfonylurea by Using "Biphase-Hyperglycemic Clamp"

Design: INTERVENTIONAL · Status: UNKNOWN · Phase: PHASE4

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

4 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Mapped RxNorm record Sitagliptin Normalized identity: sitagliptin View linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Saxagliptin Normalized identity: saxagliptin View linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Glimepiride Normalized identity: glimepiride View linked drug · Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Blank control Find medicine records · Find other trials using this name

StatusUNKNOWN

Study typeINTERVENTIONAL

Start date2012-07-01

PhasePHASE4

Conditions

Type 2 Diabetesverified · MONDO: type 2 diabetes mellitus

Interventions

SitagliptinDRUG · verified · RxNorm: sitagliptin

SaxagliptinDRUG · verified · RxNorm: saxagliptin

GlimepirideDRUG · verified · RxNorm: glimepiride

Blank controlDRUG

Sponsors & collaborators

Shanghai Jiao Tong University School of Medicinelead sponsor

Mapped research locations

ShanghaiChina1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01660386 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.